REPLIMUNE GROUP, INC. Public Float
REPLIMUNE GROUP, INC. (REPL) had Public Float of $234.50 million as of 2025-09-30, per its 10-K filed 2026-06-29.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-06-29
- 2025-09-30: Entity Public Float $234.50M.
- 2024-09-30: Entity Public Float $523.20M.
- 2023-09-30: Entity Public Float $605.60M.
- 2022-09-30: Entity Public Float $486.90M.
| Period end | Entity Public Float |
|---|---|
| 2025-09-30 | $234.50M 10-K · filed 2026-06-29 |
| 2024-09-30 | $523.20M 10-K · filed 2025-05-22 |
| 2023-09-30 | $605.60M 10-K · filed 2024-05-16 |
| 2022-09-30 | $486.90M 10-K · filed 2023-05-18 |
| 2021-09-30 | $620.30M 10-K · filed 2022-05-19 |
| 2021-03-31 | $500.20M 10-K · filed 2021-05-20 |
| 2020-03-31 | $178.00M 10-K · filed 2020-06-03 |
| 2018-09-28 | $184.00M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |